Stockscreener 앱 받기
257.25
2.76%
-7.29
전일 마감가:
$264.54
열려 있는:
$264.93
하루 거래량:
502.10K
Relative Volume:
1.15
시가총액:
$7.17B
수익:
$7.46M
순이익/손실:
$-326.53M
주가수익비율:
-19.23
EPS:
-13.3803
순현금흐름:
$-282.53M
1주 성능:
+2.76%
1개월 성능:
-24.91%
6개월 성능:
-6.29%
1년 성능:
+487.19%
1일 변동 폭
$255.39
$274.09
1주일 범위
$238.77
$274.98
52주 변동 폭
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
257.25 | 7.38B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-02 | 개시 | Wells Fargo | Equal Weight |
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up - Yahoo Finance
Praxis Precision Medicines shareholders elect directors and approve proposals at annual meeting - Investing.com India
Praxis Precision Medicines (PRAX) director receives RSU and option grants - Stock Titan
Praxis Precision Medicines (PRAX) director granted RSUs and options as equity pay - Stock Titan
Praxis (NASDAQ: PRAX) director William Young receives RSU and option grants - Stock Titan
Praxis (PRAX) director Jill DeSimone granted 1,371 RSUs and 648 options - Stock Titan
Praxis (PRAX) director awarded 1,371 RSUs and 648-share stock option - Stock Titan
Praxis (PRAX) director J. Dean Mitchell granted RSUs and stock options - Stock Titan
Praxis (PRAX) director Kindler awarded RSUs and stock options as compensation - Stock Titan
Praxis Precision Medicines (PRAX) director granted RSUs and stock options - Stock Titan
Praxis Precision Medicines (PRAX) shareholders approve board, auditor and say-on-pay - Stock Titan
PRAX Stock Quote Price and Forecast - CNN
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX) - Insider Monkey
Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies - NeurologyLive
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
PRAX: All proposals, including director elections and auditor ratification, were approved by shareholders - TradingView
Praxis Precision Medicines Inc Annual Shareholders Meeting Transcript - GuruFocus
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
Praxis Precision Medicines Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Transcript : Praxis Precision Medicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08 - marketscreener.com
Technical Reactions to PRAX Trends in Macro Strategies - Stock Traders Daily
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Praxis down on trial setback for seizure therapy - MSN
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor (PRAX) - Seeking Alpha
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings - Insider Monkey
5 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference - Investing News Network
Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE - RTTNews
Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX) - The Globe and Mail
TD Cowen Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy Pipeline - Yahoo Finance
PRAX Maintained by Oppenheimer -- Price Target Lowered to $650 - GuruFocus
PRAX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PRAX Maintains Outperform by Baird -- Price Target Lowered to $4 - GuruFocus
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive - Investor's Business Daily
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Biopharmaceutical Praxis gives new hires stock units vesting over 4 years - Stock Titan
Praxis Precision (PRAX) Sees Major Decline in Stock Value - GuruFocus
H.C. Wainwright cuts Praxis Precision Medicines stock price target on trial miss - Investing.com UK
TD Cowen cuts Praxis Precision Medicines stock price target to $550 on trial miss - Investing.com UK
PRAX Maintained by Deutsche Bank -- Price Target Lowered to $374 - GuruFocus
PRAX Maintained by Wedbush -- Price Target Lowered to $162 - GuruFocus
Truist cuts Praxis Precision Medicines stock price target on trial failure - Investing.com UK
Praxis Precision Medicines slides after vormatrigine POWER1 trial misses primary endpoint - Quiver Quantitative
Oppenheimer Adjusts Praxis Precision Medicines PT to $650 From $750, Maintains Outperform Rating - Moomoo
Praxis Precision Medicines (PRAX) Phase 2/3 Study Fails to Meet Primary Endpoint - GuruFocus
PRAX Maintained by BTIG -- Price Target Lowered to $810 - GuruFocus
Truist cuts Praxis Precision Medicines stock price target on trial failure By Investing.com - Investing.com Australia
TD Cowen cuts Praxis Precision Medicines stock price target to $550 on trial miss By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
1.27%
1.43%
자본화:
|
볼륨(24시간):